YS Biopharma repays in full $40 million 2022 R-Bridge loan

By Marisa Wong

Los Angeles, April 3 – YS Biopharma Co., Ltd. announced the full repayment of the $40 million loan borrowed under the facility agreement dated March 16, 2022 between wholly owned subsidiary YishengBio (Hong Kong) Holdings Ltd. and R-Bridge Healthcare Fund, LP as agent.

The company’s director, president and chief executive officer David Shao commented in a press release, “The repayment represents a burden lifted from the shoulders of our company. With the loan facility and its associated royalty obligations out of the way, we can now devote more resources to executing on our business plan, and move forward with an improved capital structure. This enhanced strength will give us greater flexibility in our financial operation and business operation strategies, and we are eager to forge ahead now that our debt burden has been substantially reduced.”

YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Gaithersburg, Md.-based company operates in China, the United States, Singapore and the Philippines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.